Details of the Drug
General Information of Drug (ID: DMBQTZG)
| Drug Name |
CP-70949
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer | ||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Structure | 3D Structure is Not Available |
![]() |
|||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Diabetic complication | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 5A2Y | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


